None of the patients with T2DM were treated with glucagon-like peptide 1 receptor agonist (GLP-1 RA) and only three (5%) patients were treated with sodium glucose cotransporter 2 inhibitors (SGLT2i). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.